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Abstract This study assesses the incidence and prevalence of cryptogenic fibrosing alveolitis (CFA) in awell-defined
and stable Norwegian population of 250 000 inhabitants during a period of 15 years.We conducted a file survey of all
patients (n= 376) aged16 years or older with a clinician’s diagnosis of pulmonary fibrosis (ICD 8: 517 and ICD 9: 515 and
516).Cases with a history of exposure to fibrogenic agents or with collagen vascular disease were excluded and the re-
maining158 casesweredefinedasCFA.Theaverage annualincidenceof hospitalisedCFAwas 4.3 per100 000.Nochange
was observed in the annual incidence during the15-year study period.The prevalencewas19.7 and 23.9 per100 000 by
31.12.1991and by 31.12.1998, respectively.The incidence increased considerably and significantly with age.No significant
gender differences were observed.The lack of gender differences and the increase with age were also found when the
diagnosisof CFAwasexclusivelybasedoncaseswithhospital filerecordsof breathlessness, bilateralcrackles andbilateral
shadows on chest radiograph.r2003 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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Cryptogenic ¢brosing alveolitis (CFA) is by de¢nition a
progressive pulmonary ¢brosis without a known cause.
The disease usually presents with dyspnoea, bilateral
crackles and bilateral radiographic shadowing (1,2). The
American Thoracic Society and the European Respira-
tory Society (3) recommend the use of thin-section
computer tomography and eventually video-assisted or
open lung biopsy (3) in the diagnosis of CFA but these
have until recently not been used routinely in Norway
or Great Britain (2,4).
Data on the frequency and geographic distribution of
CFA are sparse (5), and there is only one population-
based study regarding the prevalence of CFA from the
Nordic countries (6).We studied the incidence and pre-
valence of physician-diagnosed and hospitalised CFA in a
well-de¢ned adult population in Norway.Received10 June 2002, accepted in revised form10 September 2002
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Population
Bergen hospital district is located on the south-west
coast of Norway. The district incorporates the city of
Bergen and the surrounding14 municipalities. According
to the Norwegian national census data, the district had
226 659 inhabitants aged 16 or older in 1984, 244347 in
1992 and 254999 in1999. Seventy per cent of the popula-
tion lived in Bergen, which is Norway’s second largest
city. About 98% of the population were Caucasians (7).
Villages and rural areas constitute the remaining part of
the district. The annual in- and out-migration is below
3%.
Health-care system
All specialised health care and all second and third line
health services for the population are provided by two
hospitals with a total of1400 beds.The only department
of thoracic medicine is located at Haukeland University
hospital while Deaconess hospital has a department of
internal medicine. Persons living in the health district
who by chance are hospitalised in other districts are
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can be transported. Health care is free of charge and
health insurance universal.
Discharge diagnoses
At the departments, discharge diagnoses weremade un-
der the supervision of a consultant in thoracic medicine.
During the study period (1984^1998), there was a con-
sensus on theuse of the diagnostic criteria forCFA advo-
catedbyTurner-Warwicket al. (1): progressive dyspnoea,
crackles on auscultation andbilateral shadowingonchest
X-ray with no exposure to a known ¢brogenic agent.
Inclusion criteria
Potential cases over the age of 16 were identi¢ed in the
patient registers by the following physician diagnoses
(ICD 8): 517 (alia pneumonia chronica interstitialis),
517.00 (¢brosis interstitialis di¡usa pulmonumessentialis),
517.01 (¢brosis pulmonis), 517.09 (pneumonia chronica in-
terstitialis aliaNUD) (8). ICD8wasused inNorway from
1984 to1989. Since1990 ICD 9 has beenused and thuswe
included patients with ICD 9 diagnoses 515 (post-in£am-
matorypulmonary ¢brosis), 516.3 (idiopathic ¢brosing al-
veolitis), 516.8 (interstitial pneumonia) and 516.9
(unspeci¢ed alveolar and parietoalveolar pneumonopa-
thies) (9).
Case ascertainment
A computer-aided search of the hospital registers was
carried out to ¢nd all patientswho hadbeen hospitalised
between 1.1.1984 and 31.12.1998. An additional manual
search of thepatientregister of the internalmedicinede-
partment at Deaconess hospitalwas performed for1984
^ 1987 because here patient data had only been compu-
terised since1.1.1988.
For our study, we translated and modi¢ed a registra-
tion formpreviouslyusedby Scott and co-workers (10). It
incorporated demographic data, smoking history, rele-
vant symptoms, signs and lung function variables and ap-
plied diagnostic procedures.
Two physicians abstracted data from the patient re-
cords. Cases with ¢le documentation of the following
factors were excluded: pulmonary ¢brosis associated
with collagen vascular disease, intake of cytotoxic and
other potentially ¢brogenic drugs, radiotherapy and ex-
posure to asbestos as well as silica.Cases with sarcoido-
sis or allergic alveolitis from exposure tomoulds or birds
were also excluded.Data analysis
The prevalence of CFA was estimated using the cases
that were alive by 31.12.1991 and by 31.12.1998. Incident
cases were all patients diagnosed during the 15 years
from1.1.1984 until 31.12.1998.The calculation of incidence
andprevalencewasbased on thenational census data (7).
Death of patientswas veri¢edby theNorwegianpopula-
tion register, which is updated daily.
Data were entered from the registration form onto a
personal computer using Access version 1997 (11) and
analysed with SPSS version 9.0 (12). Results of lung func-
tion tests were registered as raw data and converted to
percentage predicted values using the European Com-
munity for Steal and Coal equations (13).
Genderdi¡erences, di¡erencesbetween clinical symp-
toms of prevalent and incident cases as well as the yearly
incidences were tested by the chi-square statistic. Gen-
der and age trends were calculated using logistic regres-
sion and were adjusted for the increase in the general
population. Because of multiple comparisons, the level
of signi¢cancewas de¢ned as Po0.01 (14).
RESULTS
General
Altogether 376 cases were identi¢ed with an ICD num-
ber suggestive of pulmonary ¢brosis. Thirteen patient
¢les could not be found in the archives and 30 patients
had no indication of pulmonary ¢brosis whatsoever and
must have been misdiagnosed or coded incorrectly at
discharge. Collagen vascular disease was present in the
¢les of 36 cases and other known causes of pulmonary
¢brosis were found in 69 cases.These causes were expo-
sure to asbestos, dusts, birds, radiation therapy or treat-
ment with chemotherapy and other potentially
¢brogenic drugs. Forty-one patients had been referred
from other hospital districts and 29 had been diagnosed
before 1.1.1984. Of the remaining 158 incident cases, 97
had died and 61were alive by 31.12.1998.The latter num-
ber represents the prevalent cases in1998. By 31.12.1991,
there were 48 prevalent cases. Four hundred and sixty-
¢ve hospital admissions for CFA were registered be-
tween1984 and1998.One hundred and eleven new cases
had their ¢rst admission to Haukeland hospital and 47 to
Deaconess hospital.Deceased cases with CFA in Bergen
hospital district had in average 3.3 (range1 ^ 11) hospital
admissions during a median survival of 4.1years.
Demographic characteristics and smoking
habits
The mean age at diagnosis of the incident cases was 69.2
(range 22 ^ 93) years and 45% were men (Table 1). The
mean age at diagnosis of prevalent cases by 31.12.1998
TABLE 1. Gender, smoking habits and age of incident
andprevalentcases of CFAin Bergen Hospital District
Incidentcases
1984 ^ 1998
Prevalent
cases 31.12.1998
n 158 61
Men (%) 45 34
Smokinghabits (%)
Current smokers (%) 22 25
Ex-smokers 28 23
Never smokers 41 49
Unknown 9 3
Age atdiagnosis,
mean (SD), (years)
69.2 (17) 59.2 (19)
TABLE 2. Percentagesa of incident and prevalent cases
of CFAwith dyspnoea, crackles, bilateral interstitial sha-
dowsonchestradiograph, restrictive spirometricpattern
andreduced TLCO
Incidentcases
1984 ^ 1998
Prevalent
cases
per 31.12.1998
n 158 61
Dyspnoea 87 79
Bilateral basal crackles 77 62
Bilateral interstitial shadows 91 89
Restrictive
spirometric patternb
55 46
TlCOo80% of predicted 83 80
aInformation was available on dyspnoea, crackles,
chest radiograph, spirometry and di¡usion capacity in
151,157,158,97, 65 of the incident cases and in 57, 60, 61,46,
35 of the prevalentcases
bDe¢ned as forced vital capacity (FVC) o80% of pre-
dicted and forced expiratory volume in 1s (FEV1)/FVC
40.7.
430 RESPIRATORYMEDICINEwas 59.2 (range 22 ^ 90) and 34%weremen.Only sixmen
and three women (6% of all cases) were diagnosed with
CFA16 ^ 34 years old. Sixty-¢vemen and 84 women, al-
together 83% of the cases, were diagnosed when they
were over 54 years old (Fig. 1). Smoking habits did not
di¡er between incident and prevalent cases (Table 1).
More men (68%) than women (36%) were ever smokers
(Po0.005). No signi¢cant di¡erences in smoking habits
were observed between prevalent and deceased cases
(P=0.22).
Clinical characteristics
Dyspnoea was the most common symptom recorded in
the ¢les.Crackles on auscultationwere recorded in two-Age at 
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FIG. 1. Age of incidentcaseswith CFAin 5 year groups.thirds of the cases and almost nine out of10 had bilateral
shadowing on chest radiograph (Table 2).
Spirometry was recorded in 61% and di¡usion capacity
in 41% of the incident cases and in 75 and 57% of the pre-
valent cases. Spirometry was performed in 84% of the
cases below the age of 75 years and in 36% of the cases
above (Po0.002).Di¡usion capacity was measured in 64
and 15% (Po0.001) of the respective groups. Fewer de-
ceased than prevalent cases had performed TLCOdiagnosis
85+
80-84
75-79
70-74
65-69
60-64
55-59
-54
CRYPTOGENICFIBROSINGALVEOLITIS 431(P=0.002) and simple spirometry (P=0.012). A restric-
tive lung function pattern de¢ned as forced expiratory
volume in 1 s/forced vital capacity (FEV1/FVC)40.7 and
FVCo80% of expected was present in half of the cases
that had performed the test. Reduced di¡usion capacity
was present in 80% of the cases (Table 2).
Incidence andprevalence
Themediannumber of incidentcaseswas11per year.The
number of new cases per year varied from 5 to17 during
the study period (Fig. 2) yet the di¡erenceswere not sig-
ni¢cant (P=0.47).
The average annual incidence of hospitalised CFAwas
4.3 per100 000 inhabitants over16 years of age. Inmen it
was 4.0 (95% CI: 3.1^4.9) and in women 4.6 (95% CI: 3.7^
5.6) per 100 000 (Table 3). The prevalence was 23.4 perYear of 
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FIG. 2. Newcaseswith CFAin Bergen Health Districtdiagnosed
TABLE 3. Hospitalised cases and incidence of CFA per 100 00
Cases and incidencewiththe three recorded criteria dyspnoea,
Hospitalised cases
Age (years) Men Women Total
n Incidence n Incidence n Incidence
16^34 6 0.8 3 0.4 9 0.6
35^54 10 1.6 8 1.4 18 1.6
55^74 22 6.1 36 8.6 58 7.5
75+ 33 30.6 40 19.3 73 23.3
Total 71 4.0 87 4.6 158 4.3100 000 inhabitants by 31.12.1998 (95% CI: 14.9^33). The
prevalence of hospitalised CFA per 100 000 by 31.12.1991
was 19.7 (95% CI: 14.1^25,3). The di¡erence between the
prevalence in1991and1998 was not signi¢cant (P=0.31).
In the logistic regression, there was a signi¢cant in-
crease of both incidence and prevalence with age
(Po0.01). A non-signi¢cant female predominance in inci-
dence andprevalencewas found taking all age groups to-
gether (P=0.71). There was no signi¢cant interaction
between age and gender (P=0.54).
Incidence and prevalence did not di¡er signi¢cantly
(P=0.79) between inhabitants of the city of Bergen and
the surrounding municipalities. Median survival of inci-
dent cases was 4.1years (95% CI: 3.1^5.2).
In 98 cases of CFA dyspnoea, bilateral crackles and bi-
lateral radiographic shadowing were recorded in the
hospital ¢les. Calculating the incidence based on these
cases it was 2.3 and 3.0 per100 000 per year in men anddiagnosis
1998
1997
1996
1995
1994
1993
1992
1991
between1984 and1998.
0 inhabitants during 1984^1998 in Bergen Hospital District.
crackles andbilateral shadows on chest radiograph
Hospitalised caseswiththree recorded criteria
Men Women Total
n Incidence n Incidence n Incidence
2 0.3 0 F 2 0.1
4 0.7 4 0.7 8 0.7
13 3.6 25 6.0 38 4.9
22 20.5 28 13.6 50 15.9
41 2.3 57 3.0 98 2.7
TABLE 4. Hospitalised cases and prevalence by 31.12.1998 of CFA per100 000 inhabitants in Bergen Hospital District.Cases
andprevalencewiththe three recorded criteria dyspnoea, crackles andbilateral shadows on chest radiograph
Hospitalised cases Hospitalised caseswith 3 recorded criteria
Age (years) Men Women Total Men Women Total
n Prevalence n Prevalence n Prevalence n Prevalence n Prevalence n Prevalence
16^34 5 10.3 3 6.4 8 8.4 2 4.1 0 F 2 2.1
35^54 7 16.1 8 19.3 15 17.6 2 4.6 4 9.6 6 7.1
55^74 6 24.8 14 52.1 20 39.2 3 12.4 7 26.1 10 19.6
75+ 3 35.2 15 96.7 18 74.9 2 23.4 9 58.0 11 45.8
Total 21 16.8 40 30.7 61 23.4 9 7.2 20 15.3 29 11.4
432 RESPIRATORYMEDICINEwomen, respectively (Table 3).The prevalence using the
same diagnostic criteria was 7.2 per 100 000 in men and
15.3 per100 000 inwomen (table 4). Incidence andpreva-
lence increasedwith age (Po0.01) but gender di¡erences
(P=0.48) were not observed.
DISCUSSION
In a community study inNorway over a time period of15
years, we observed an annual incidence of hospitalised
CFA of 4.3 and a prevalence of 23.4 per 100 000 inhabi-
tants aged16 and older.There were no overt di¡erences
between men and women. A marked increase with age
was present in both incidence and prevalence.
Methodological considerations
The frequency of CFA in this population is estimated for
patients requiring hospitalisation. This will underesti-
mate the incidence andprevalence in the general popula-
tion, as less symptomatic cases are not referred to a
hospital in the health district. The inclusion of patients
was based on consultant physicians’ ICD diagnoses. The
validity of the clinical diagnosis and coding of CFA is con-
troversial. A study from the UK showed a high accuracy
of ICD 9 code 516.3 (idiopathic ¢brosing alveolitis) but
low reliability of other ¢brosis-related diagnoses (15).
Meanwhile, a study from the U.S.A. (16) concluded that
the agreement between clinical diagnoses of CFA and
death certi¢cate datawas low.On the other hand, physi-
cians’ diagnoses are a well-established and practical tool
in epidemiological research, andhavebeenused in earlier
studies of CFA (17). Furthermore, we initially included a
broadrange of ICDdiagnoses to reduceunderestimation
of the frequency of CFA.
In a proportion of our cases, not all the typical clinical
¢ndings of CFAwere recorded in the ¢les. It has earlier
been noted that the presence of symptoms and signs in
CFA is variable (18,19). Turner-Warwick et al. (1) found
dyspnoea in 92% and bilateral crackles in 96% and thechest radiograph was normal in 2% of 220 patients ad-
mitted to a tertiaryreferral centre in theU.K. In theBrit-
ishThoracic Society Study (2), the chest radiograph was
normal in 2% of the CFA cases and10% had no dyspnoea
on exertion.The variability of the clinical ¢ndings in pre-
vious aswell as in our study is probably a consequence of
the inclusion of di¡erent histological subgroups of CFA
and the patients may have been at di¡erent stages of
the disease.Demedtsetal. (5) recommended to diagnose
and classify CFAor idiopathic pulmonary ¢brosis accord-
ing to the guidelines of the AmericanThoracic Society
and the EuropeanRespiratory Society (3).Here the term
idiopathic pulmonary ¢brosis is reserved for cases with
the typical pattern of usual interstitial pneumonia on
high-resolution computed tomography and eventually
surgical lung biopsy specimens. Since our study started
long before high resolution computed tomography was
available in our hospitals and before the consensus was
obtained we had to rely on the clinical practice at that
period of time. Therefore, our estimates of incidence
andprevalence apply toCFA as de¢nedbyclinical criteria
(1). Thus, the whole spectrum of idiopathic interstitial
pneumonias is included and our results are not limited
to patientswithusual interstitial pneumonia (3).To which
extent the frequencyof CFAwill changewhen high-reso-
lution computed tomographybecomesmorewidelyused
requires further investigation.
In our retrospective study, results of simple lung func-
tion testswere available in about two-thirds of our cases.
We have few lung function data in patients above the age
of 75 years probablybecause it ismore di⁄cult to obtain
acceptable test results in the elderly. However, in the
prospective British Thoracic Society study of CFA (2)
spirometry was recorded in 96% and di¡usion capacity
in 75% of cases.
Incidence estimates
The incidence of CFA varies between 0.9 and 9.1 per
100 000 in di¡erent countries (Table 5). These large
TABLE 5. Annual incidence and prevalence per100 000
inhabitants of CFA from population-based studies in six
countries
Country Incidence Prevalence
USA (22) 9.1 16.7
Japan (23) F 10.0
UK (10) F 6.0
Spaina (24) 1.3 F
Czech Republic (25) 0.9 12.1
Finland (6) F 16^18
Norway (present study) 4.0 23.4
aIdiopathic interstitialpneumonias.
CRYPTOGENICFIBROSINGALVEOLITIS 433di¡erences have been attributed to diagnostic impreci-
sion, lack of internationally accepted classi¢cations and
weaknesses of study design (5,20,21). The incidence in
Bergen lies between that found in a region in southern
Spain and in Moravia and Selesia, Czeck Republic on one
side and inNewMexico,U.S.A. on the other side (Table 5).
In the comprehensive population-based study from
Bernalillo county,NewMexico (22) allnewcases of inter-
stitial lung diseases were registered over a 2-year period
in a population of nearlyhalf amillion inhabitants. All pul-
monary andprimary-care physicians as well as internists
in this regionwere informedinwriting about theregister
and asked to submit all patients with interstitial lung dis-
eases. A rather unspeci¢c clinical or pathological diagno-
sis was the basis for all referrals and was also used to
establish a ¢nal diagnosis in the register.The incidence of
CFAwas10.7 per100 000 per year in men and 7.4 in wo-
menwhile the average incidencerates in BergenHospital
District are only half as high.Onepossible reason for this
di¡erence can be the longer observation period of 15
years in the present study, whichwas only 2 years in the
study from New Mexico (22).The number of new cases
of CFA varied in Bergen more than threefold from year
to year.Given our longer surveillance period, the real dif-
ferences of the incidence between the two geographical
areasmayhavebeen less. Another factor contributing to
the higher incidence couldbe that physicians in Bernalillo
County referredmilder cases of CFA not necessarily re-
quiring hospitalisation. Finally, one has to take into ac-
count that environmental factors may in£uence the
occurrence of CFA. Bernalillo County is a major mining
area (22) while Bergen hospital district has nomining in-
dustry and only littlewood andmetal industry.
Prevalence estimates
The prevalence of CFA varied in previous studies be-
tween 6 and18 per 100 000 (Table 5).Our prevalence of
24 per100 000 is comparatively high, most likely because
we included not only cases with usual interstitial pneu-monia but also other types of idiopathic interstitial pneu-
monias with a longer survival. In the nationwide study
from Finland (6), thin-section computer tomography
was preformed in a majority and lung biopsies in nearly
one-third of the patients thus reducing the number of
cases with an idiopathic interstitial pneumonia other
than usual interstitial pneumonia.
A spirometry survey (26) conducted in a random sam-
ple of the population aged18^73 years of Bergen and11
surrounding communities showed a restrictive spiro-
metric pattern (FEV1/FVC40.70 and FVCo80%) in 9%
of men and 7% of women and the prevalence increased
heavily with age. The causes of this rather high preva-
lence of a restrictive spirometric pattern are not known.
In any case, CFA can only explain a small fraction of the
occurrence of the restrictive spirometric pattern. This
large discrepancybetween theprevalence of hospitalised
CFA and the restrictive spirometric pattern in the com-
munity should be further examined.
In the national mortality statistics CFA (ICD 8: 517,
ICD 9: 515, 516.3) was registered as primary cause of
death in 893 patients in Norway between1982 and1995
(27) rendering a death rate of 1.4 per 100 000 per year.
No gender di¡erence was observed.The Norwegian Pa-
tient Register (28) has registered 3239 admissions for
CFA between 1990 and 1996. This represents an admis-
sion rate of 9.3 per100 000 per year for thewhole coun-
try. Given our prevalence of 24 per 100 000, the yearly
admission rate in Bergen hospital district would be 19
per100 000 inhabitants above the age of 16 years, when
each patient had in average 3.3 admissions during amed-
ian survival of 4.1years.This is somewhat higher than the
national hospital admission rate.
Gender
In their community study, Coultas and co-workers (22)
found that CFA had a male-to-female ratio of 1.5. Hub-
bard et al. (29) in a case^ control study reported a
male-to-female ratio of 2.2. On the other hand, Hodg-
son and co-workers (6) in their recent nationwide study
from Finland found no gender di¡erences in the preva-
lence of CFA. In a German registry, even a slight female
predominancewas registered (30).We didnot ¢nd a pre-
dominance of men in the incidence and prevalence of
CFA in this Norwegian population but rather a female
predominance in the prevalence estimate taking all age
groups together.
The lackof a male predominance in our study couldbe
related to the fact that few men in Bergen hospital dis-
trict work in polluting industry (31). Smoking is most
probably a risk factor for CFA (30,32). Norwegian wo-
men are among the heaviest smokers in the world (34)
and 36% of thewomen in our study were current or ex-
smokers. Thus, the high number of smoking women in
434 RESPIRATORYMEDICINEour study could partially explain the high fraction of fe-
male cases. Another possible explanation is that women
if exposed to an equivalent amount of tobacco smoke
maybe at higher risk to develop respiratory disease than
men. Accordingly, Langhammer and co-workers (35)
found that Norwegianwomen had a higher frequency of
respiratory symptoms than men given the same burden
of tobacco smoke.
The observation in earlier studies of a male predomi-
nance has given rise to the hypothesis that CFA could be
caused by occupational hazards, namely dusts from
wood and metal (27). Since we do not ¢nd a clear male
predominance our data cannot support this hypothesis.
Age
A prominent ¢nding in our study is the increase of CFA
with age.The age trend was similar for men and women
as well as for prevalent and incident cases.This con¢rms
CFA as a disease of the elderly (3,21).
Themean age at diagnosis of our incident caseswas 69
years, which is similar to that observed in the 588 pa-
tients (67 years) of the British Thoracic Society Study
(2). In the study by Coultas and co-workers (23), the
mean age was 61 years probably re£ecting referral bias
in favour of younger patients.
The prevalent cases in our study are in average 10
years younger than the incident cases. This is probably
due to a high fraction of young patientswith a long survi-
val among the prevalent cases.
The lowermean age at diagnosis of the prevalent than
of the incident cases in our study is due to a higher frac-
tion of living cases that were diagnosed at relatively
young age.These meet the inclusion criteria of the pre-
sent study but probably do not have usual interstitial
pneumonia, which usually has a shorter survival.
In summary, the incidence of hospitalised CFA is lower
in this population-based study from Norway than in
New Mexico, U.S.A. but higher than in other European
countries and Japan.The prevalence is similar to that ob-
served recently in Finland. Probably, diagnostic di¡er-
ences explain a part of these variations. Incidence and
prevalence increase considerably with age. No gender
di¡erencewas observed.This is in contrastwith previous
¢ndings of a male dominance of CFA, which has been as-
cribed to occupational exposure to various ¢brogenic
agents. Further studies into the occupational history of
women as well as men in our patient population and in-
ternational comparisons arewarranted to pursue thehy-
pothesis that environmental hazards play a role in the
aetiology of CFA.
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